Trials / NCT05926583
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
Underway, not enrolling Phase 3 Gene therapy
- Sponsor
- MeiraGTx Ocular UK Ltd
- Treatment
- AAV5-hRKp.RPGR; AAV5-hRKp.RPGR
- Gene
- RPGR
- Conditions
- Retinitis Pigmentosa
- Ages
- 5 Years to no upper limit
- Enrollment
- 4 participants
- Started
- 2023-09-12
- Main results expected
- 2027-06-30
- Results posted
- Not yet
- Record last updated
- 2026-09-25
What the study is testing
The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
Where it runs
Japan (1)
- National Hospital Organization Tokyo Medical Center, Meguro-ku